, and spoAlzheimer disease (AD) is the most common neuro-radic late onset AD . The APOEdegenerative disorder for individuals over the age of 4 allele acts in a dose-dependent fashion, with risk in-40. AD has a complex etiology, and it is likely that mul-creasing (and age-at-onset decreasing) with the numtiple genes, acting independently and/or interacting, ber of APOE-4 alleles (Corder et al., 1993) , a result affect the risk of developing AD. Several genes in-confirmed in many different populations (Roses et al., volved with AD have been described already, but only 1995). Although the APOE-4 allele is involved in half the APOE gene on chromosome 19q has been shown to of all AD cases (Roses et al., 1996), a substantial numaffect the risk of the common late onset form of AD. ber of individuals with the APOE-4 allele escape AD, a 1 -Antichymotrypsin (AACT) is a major component of and a substantial number of AD cases have no APOEthe amyloid plaques found in the brains of AD patients, 4 allele. This result suggests that other genes may modand an allele in its gene has been proposed to increase ify the effect of the APOE-4 allele. the risk of developing AD when also associated with a 1 -Antichymotrypsin [AACT] has been suspected to the APOE-4 allele. We have examined the role of this play a role in AD since it was first shown to bind the AACT polymorphism in a large set of families and spob-amyloid peptide in AD brains (Abraham et al., 1988; radic cases, and do not see any effect, either alone or
INTRODUCTION
and has two alleles with nearly equal frequencies in Alzheimer disease (AD) is the most common neurode-the general population. AACT is a natural candidate generative disorder of the elderly, affecting over 4 mil-gene to examine for additional genetic effects on AD, lion individuals in the United States (Max, 1993) . On-and potentially for interaction with the APOE effect. set is variable, and is generally divided into early (õ65) Recently, (Kamboh et al., 1995) reported that in indiand late (ú65) onset forms. AD is also genetically com-viduals carrying an APOE-4 allele, the AACT-TT genoplex. Autosomal dominant mutations in the APP gene type appeared to be protective, while the AACT-AA (on chromosome 21) (Goate et al., 1991) , in the preseni-genotype appeared to confer a two-to three fold inlin I gene (on chromosome 14) (Sherrington, et al., creased risk. 1995) , and in the presenilin II gene (on chromosome 1) (Levy-Lehad et al., 1995; Rogaev et al., 1995) In 1993, an association between AD and the apolipoCenter (Duke-ADRC), the Indiana Alzheimer Disease Center Naprotein E (APOE)-4 allele was reported in both familial tional Cell Repository, the UCLA Neuropsychiatric Institute, and the UCLA Alzheimer Disease Research Center as part of long term familial studies of AD. To be part of these studies, families must 1 To whom all correspondence should be addressed at Molecular Neurogenetics Unit, Massachusetts General Hospital, Building 149, have two or more sampled affected individuals meeting the standard clinical criteria for AD (McKhann et al., 1984 Note. No significant differences in the AACT allele frequencies are observed between APOE-4 allele carriers and non-APOE-4 allele carriers. The AACT alleles are in Hardy-Weinberg equilibrium. typed individuals. The average age-at-onset for the affected individuData analysis. Lod scores were calculated using the LINKAGE package (Lathrop et al., 1984) assuming an autosomal dominant als was 69.9 ({7.4) years, 40% were male, and virtually all families mode of inheritance for AD with an age-dependent penetrance as were Caucasian in origin.
previously described (Pericak-Vance et al., 1991; Locke et al., 1995) . The 576 additional patients with no apparent family history (spoThe penetrance varied from 0.4% at age 40 to 99% after age 90. radic cases) were identified through the MGH-ADRC, the DukeNo phenocopy rate was assumed. Affected-Pedigree-Member (APM) ADRC, or the Alzheimer Disease Clinic at Boston University. All analysis (Weeks and Lange, 1988) was also performed on these famipatients received a clinical diagnosis of Alzheimer disease in accorlies using the f(p) Å 1/sqrt(p) weighing function. This function has dance with standardized criteria (McKhann et al., 1984) . Our experibeen suggested as the most robust function to use (Weeks and Lange, ence indicates that over 95% of clinically diagnosed AD patients will 1988). be confirmed upon autopsy (Pericak-Vance et al., 1991) . The average Tests of differences in allele and genotype frequencies were perage-at-onset was 69.1 ({8.6) years, 37% of the patients were male, formed using either the x 2 test statistic or deviations from the binoand virtually all were Caucasian. The 535 controls were also ascermial distribution. tained and sampled. These included 295 spouses of AD patients Odds ratios were calculated using standard logistic regression con-(mean age of examination was 70) and 240 unrelated controls of all trolling for age and sex. Two models were tested, one including only ages. All controls had no evidence of dementia upon initial contact.
APOE and AACT main effects and a second allowing for interaction Genotyping. Blood samples were obtained, after appropriate inbetween loci.
The differences between models was tested using the formed consent, from all subjects, and DNA was obtained using stan-likelihood ratio criterion. dard techniques either by direct extraction or from lymphoblast cultures. APOE and AACT genotypes were determined as previously et al., 1995; Kamboh et al., 1995) . All resulting gels A total of 576 sporadic patients and 535 controls were and autoradiograms were visually scored, and the data were entered into computerized database systems. examined for both APOE and AACT genotypes. Table   TABLE 2 Joint Distribution of APOE and AACT Genotypes AACT genotypes Note. In each subject group the percentages reflect the percentage of the APOE genotypes for each of the three AACT genotypes. No significant differences are observed. All genotypes are in Hardy-Weinberg equilibrium. 1 presents the allele frequencies of both APOE and scores. We also examined for linkage and/or association by using the APM (Weeks and Lange 1988) method of AACT. As expected, the APOE-4 allele is over-represented in the AD patients vs. the controls (0.43 vs. analysis and no evidence of linkage or association was found (P ú 0.90). Although the numbers are small, 0.16, P ú 0.0001), while the control frequency is not significantly different from those reported elsewhere. there was no evidence of any interaction between APOE-4 and the AACT-A allele in the families. For AACT, there is no significant difference in the frequency of the T allele between the affecteds and the controls (0.48 vs. 0.49, P Å 0.54), and the control fre-DISCUSSION quency is not different from those reported elsewhere (Kamboh et al., 1995) . Table 2 presents the joint APOE Our dataset combines and expands upon two preand AACT genotypes. The distributions of the APOE viously published datasets  and AACT genotypes are in Hardy-Weinberg equilib- Locke et al., 1995) and thus refines the estimated odds rium for both the controls and the affected populations. ratios for the dose-dependent effect of APOE-4. Given
RESULTS

described (Locke
To examine for potential interactions between APOE that the risk related to the APOE-4 allele is neither and AACT alleles, we performed logistic regression to specific nor sensitive, it is reasonable to look for other calculate odds ratios for the various genotype combina-factors, both environmental and genetic, that may modtions. We first calculated a main model examining the ify this APOE-4-related risk. The AACT-A allele has independent effects of the APOE-4 allele and the recently been proposed as such a modifying factor AACT-A allele. The dose-dependent effect of the APOE- (Kamboh et al., 1995) . In the initial study (Kamboh et 4 allele was confirmed, while no effect of the AACT-A al., 1995) , no independent effect of the AACT polymorallele was seen (Table 3) . A second logistic regression phism was seen, while the effect of the APOE-4 allele was performed to examine specifically for interactive was strong. In a joint analysis the odds ratios for haveffects. No significant additional effects were seen (Ta-ing AD were doubled in heterozygous APOE-4 individuble 3), and the two models were not significantly differ-als who also had the AACT-AA genotype, and tripled ent from each other (x 2 Å 7.21, 4df, P Å 0.12). in the double homozygotes APOE-44, AACT-AA. Our We also examined the potential effect of AACT in 67 data do not support this finding. The AACT-A allele families segregating AD. Lod scores were calculated has no effect either independently or interactively. This assuming an autosomal dominant mode of inheritance. was true even using various subsets of control samples Two different models were tested. The first used the (data not shown). We also designed our study with infull information from both affecteds and their unaf-ternal replication. Approximately 1/2 of the overall spofected relatives. This model excluded linkage to 11 cM radic patient data were generated on a dataset indearound the AACT gene, with no positive lod scores at pendently collected and analyzed at each site (MGH any recombination fraction. The second used pheno-and Duke). The results of each subset were virtually typic information from only the affected individuals (an identical. affecteds-only analysis). This analysis excluded linkage
The difference between the initial (Kamboh et al., 1995) study and our study could arise for several reato 9 cM around the AACT gene, with no positive lod tion of a missense mutation of the amyloid precursor protein gene sons. One possibility is that the study (Kamboh et al., with familial Alzheimer's disease. Nature 349: 704-706. 1995) was a chance positive result. Another possibility Kamboh, M. I., Sanghera, D. K., Ferrell, R. E., and DeKosky, S. T. is some difference in either the patient or the control (1995 In diseases of complex genetic etiology such as AD, Levy-Lehad, E., Wasco, W., Poorkaj, P., et al. (1995) . Candidate gene identifying underlying susceptibility genes is a difficult for the chromosome 1 familial Alzheimer's disease locus. Science process. Thus replication is a key element in determin-269: 973-977. ing which genes have substantial and important efLocke, P., Conneally, P. M., Tanzi, R. E., et al. (1995) . APOE and fects. Our internal, independent replication design Alzheimer disease: Examination of allelic association and effect on helps to address this problem, and we would advocate age at-onset in both early and late-onset cases. Genet. Epidemiol.
its use in dissecting complex genetic etiologies.
12: 83-92. Max, W. (1993) . The economic impact of Alzheimer's disease. Neurology, 43(Suppl.4): 56-510.
